Reducing immune inhibition induced by SIGLEC-15
AssigneeInnovative Cellular Therapeutics Holdings, Ltd.
InventorsZhiyuan Cao, Chengfei Pu, Lei Xiao
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a modified cell comprising a polynucleotide encoding a secretable scFv binding SIGLEC-15 and/or encoding a dominant negative form of CD44. In embodiments, the modified cell further comprises an antigen-binding molecule, which for example, is a CAR comprising an antigen-binding domain, a transmembrane domain, and an intracellular signaling domain.
Claims19
A polynucleotide comprising a polynucleotide encoding an antibody binding SIGLEC-15 and a polynucleotide encoding a Chimeric Antigen Receptor (CAR), wherein the antibody binding SIGLEC-15 comprises amino acid sequence SEQ ID NO:
- 115 or 116.
A polynucleotide comprising a polynucleotide encoding an antibody binding SIGLEC-15, wherein the antibody comprises amino acid sequence SEQ ID NO:
- 115 or 116.
Dependencies are inferred from the claim text.